{"schema_version":"secwatch.filing_event.v1","accession":"0001799191-23-000020","form_type":"8-K/A","ticker":"TOI","cik":"0001799191","company_name":"Oncology Institute, Inc.","filed_at":"2023-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.644600+00:00","generated_at":"2026-06-14T01:28:02.074334+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"The Oncology Institute names Daniel Virnich as CEO, Brad Hively becomes Vice Chairman","bullets":["Brad Hively steps down as CEO effective June 30, 2023, becomes Vice Chairman.","Daniel Virnich, current President, appointed CEO effective June 30, 2023.","Hively receives salary continuation, COBRA premiums for 12 months, and 50% of 2023 annual bonus at Board discretion.","All unvested restricted stock units vest through June 30, 2024 per existing vesting schedules.","Transition was not the result of any disagreement with the Company."],"urls":{"canonical":"https://secwatch.observer/filing/0001799191-23-000020","json":"https://secwatch.observer/filing/0001799191-23-000020.json","markdown":"https://secwatch.observer/filing/0001799191-23-000020.md","text":"https://secwatch.observer/filing/0001799191-23-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799191/000179919123000020/0001799191-23-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799191/000179919123000020/toi-20230608.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T01:28:02.074334+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1cd4d482e4","claim":"Brad Hively changed role as Vice Chair of the Board at Oncology Institute, Inc..","evidence_excerpt":"Brad Hively will transition from his role as Chief Executive Officer of The Oncology Institute, Inc. (the “Company”) to Vice Chair of the Board of Directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919123000020/0001799191-23-000020-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"Vice Chair of the Board"}],"fact_type":"executive_change"},{"claim_id":"75d80b6f48","claim":"Daniel Virnich was appointed as Chief Executive Officer at Oncology Institute, Inc..","evidence_excerpt":"the Board appointed Daniel Virnich, the Company’s current President, as Chief Executive Officer effective as of June 30, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919123000020/0001799191-23-000020-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}